Chemizon and CrystalGenomics Announce Collaboration
News Jul 11, 2007
As part of this program, Chemizon’s scientists will develop and optimize new synthetic routes that are designed to reduce CG’s overall manufacturing costs and accelerate their development timelines.
“As CrystalGenomics continues its rapid growth, we regularly seek to identify reliable partners whose core competencies augment our internal capabilities. We were impressed by Chemizon’s process chemistry team and their technical capabilities. In addition, Chemizon’s proposal provided the best combination of scientific merit and financial creativity. We look forward to a successful partnership,” said Seonggu Ro, Ph.D., Vice President and CTO of CrystalGenomics.
“We are very pleased that CrystalGenomics chose Chemizon to execute this research program. Chemizon has assembled an outstanding scientific team and continues to build a world-class research organization with expertise in drug discovery and process research. This agreement with a top-tier life science company like CrystalGenomics, validates our efforts,” said Anthony Piscopio, Ph.D., Chairman and CEO of Chemizon Inc.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019